Mirae Asset Global Investments Co., Ltd. Trevi Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $30.9 Billion
- Q3 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,708 shares of TRVI stock, worth $53,341. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,708
Previous 3,930
19.8%
Holding current value
$53,341
Previous $21,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TRVI
# of Institutions
174Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...